Global Infectious Diseases Market – Industry Trends and Forecast to 2031

Infectious Diseases Market Analysis and Size

The infectious disease market, particularly concerning bacterial infections, is witnessing a surge in demand for rapid diagnostics and effective treatments due to the rise of antibiotic-resistant strains. Companies such as Cepheid and Tetraphase Pharmaceuticals are capitalizing on this trend by developing innovative testing platforms and novel antibiotics, respectively. This reflects a growing market need for advanced solutions to combat bacterial infections, driving investment and innovation in the field.

Global infectious diseases market size was valued at USD 20.52 billion in 2023 and is projected to reach USD 32.14 billion by 2031, with a CAGR of 5.77 % during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation       

Market Definition

Infectious diseases are illnesses caused by harmful germs such as bacteria, viruses, fungi, or parasites. These germs can spread easily from person to person through various ways such as direct contact, contaminated food or water, and even through the air. Common instances include the flu, common cold, tuberculosis, and COVID-19. Prevention measures such as vaccination, proper hygiene, and avoiding close contact with sick individuals are important in controlling their spread.

Infectious Diseases Market Dynamics

Drivers

• Increasing Demand for Rapid Diagnostic Solutions

The escalating demand for rapid diagnostic solutions is a key driver in the infectious disease market due to its pivotal role in the timely detection and management of infections. Rapid tests enable healthcare providers to swiftly diagnose diseases, facilitating prompt initiation of treatment and implementation of preventive measures. This addresses the pressing need to contain outbreaks, minimize transmission rates, and mitigate the associated healthcare burden. Consequently, the market is witnessing a surge in innovation and investment to meet this growing demand effectively. For instance, during the COVID-19 pandemic, the demand for rapid antigen tests surged globally. These tests provided quick results, aiding in identifying infected individuals swiftly, implementing isolation measures, and controlling the spread of the virus within communities.

• Growing Awareness of Preventive Measures

The increasing awareness of preventive measures in the infectious disease market is promoting proactive health behaviors and reducing disease transmission. Heightened public awareness campaigns, coupled with education initiatives, encourage individuals to adopt preventive measures such as vaccination, hand hygiene, and sanitation practices. This leads to a decrease in disease incidence and severity, driving the demand for preventive products and services and fostering a healthier population overall.

Opportunities

• Environmental Changes Impacting Disease Transmission

Environmental changes, such as climate change and urbanization, significantly influence disease transmission dynamics. Altered weather patterns and habitat destruction can lead to shifts in vector distribution and increase the spread of vector-borne diseases such as malaria and dengue fever. Additionally, urbanization creates favorable conditions for disease transmission, including overcrowding and inadequate sanitation. These changes drive the emergence and reemergence of infectious diseases, necessitating adaptation strategies and investments in disease surveillance, prevention, and control measures. For instance, rising temperatures and changing precipitation patterns due to climate change have expanded the geographic range of mosquito vectors responsible for diseases such as dengue fever and Zika virus. This has led to increased transmission rates in previously unaffected regions, posing new public health challenges.

• Government Initiatives for Infectious Disease Control

Government initiatives play a crucial role in driving infectious disease control efforts by providing funding, implementing policies, and coordinating responses. Through initiatives such as vaccination campaigns, disease surveillance systems, and public health education, governments aim to prevent, detect, and mitigate the spread of infectious diseases. These efforts not only safeguard public health but also contribute to economic stability by reducing healthcare costs and productivity losses associated with disease outbreaks, fostering a healthier and more resilient population.

Restraints/Challenges

• Poor Sanitation in Developing Regions

Poor sanitation in developing regions for infectious diseases is creating environments for disease transmission. Inadequate access to clean water and sanitation facilities increases the risk of waterborne diseases such as cholera and diarrheal illnesses. In addition, improper waste management leads to the proliferation of vectors such as mosquitoes, contributing to the spread of vector-borne diseases such as malaria and dengue fever. For instance, in areas with poor sanitation infrastructure, such as certain rural communities in sub-Saharan Africa or South Asia, contaminated water sources are common. This leads to frequent outbreaks of waterborne diseases such as typhoid fever, and hepatitis A, affecting public health significantly.

• Economic Constraints Affecting Healthcare Spending

Economic constraints act as a significant restraint in the fight against infectious diseases by limiting the financial resources available for healthcare spending. In regions with constrained budgets, governments and individuals may struggle to afford essential medical supplies, vaccines, and treatments. This can lead to inadequate disease prevention and control measures, hindering efforts to contain outbreaks and resulting in higher morbidity and mortality rates. As a result, infectious diseases disproportionately affect socioeconomically disadvantaged populations, exacerbating existing health disparities.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In January 2023, Thermo Fisher Scientific Inc. launched its CE – IVD marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit. This advancement enhances therapeutic efficacy, fosters viral resistance monitoring, and propels innovation within the infectious disease market
• In July 2022, Roche launched Elecsys HCV Duo, an immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCBv) antigen and antibody status form a single human plasma or serum sample. This innovation enhances diagnostic efficiency, expedites patient care, and drives advancements in infectious disease management, fostering market expansion
• In March, 2020, Becton Dickinson and Company (BD) announced the release of a new Rapid Serology Test to identify COVID-19 exposure. The procedure is a new point-of-care test that can identify present or previous exposure to COVID-19 in less than 15 minutes by detecting antibodies in blood. Providing results within 15 minutes, it expedites diagnosis, informs patient management, and bolsters surveillance efforts, catalyzing growth and innovation within the infectious disease market

Infectious Diseases Market Scope

The market is segmented into four notable segments based on product and services, technology, disease type, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product and Services

• Assays
• Kits and Reagents
• Instruments
• Services
• Software

Technology

• Immunodiagnostics
• Clinical Microbiology
• Polymerase Chain Reaction (PCR)
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• DNA Sequencing and Next-Generation Sequencing (NGS)
• DNA Microarray
• Other Technologies

Disease Type

• Hepatitis
• Human Immunodeficiency Virus (HIV)
• Chlamydia Trachomatis Genital Infection and Gonorrhea (CT/NG)
• Hospital-Acquired Infections (HAIS)
• Human Papillomavirus (HPV)
• Tuberculosis (TB)
• Influenza
• Other Infectious Diseases

 End User

• Hospital/Clinical Laboratories
• Reference Laboratories
• Physician Offices
• Academic/Research Institutes
• Other End Users

Infectious Disease Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by based on product and services, technology, disease type, and end user as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, rest of Europe, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.

North America dominates the infectious diseases market due to the high prevalence of improved healthcare infrastructure, increasing occurrences of infectious diseases, adoption of advanced technology, and rising number of clinical laboratories.

Asia-Pacific is expected to be the fastest growing region in the infectious disease market due to the rising health awareness among the people and growing demand of advanced medical technology.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The market also provides you with a detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for the market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for the historic period 2016-2021.

Competitive Landscape and Infectious Diseases Market Share Analysis

The market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major players operating in the market are:

• Abbott (U.S.)
• BD (U.S.)
• bioMérieux (France)
• Bio-Rad Laboratories Inc. (U.S.)
• Danaher (U.S.)
• DiaSorin S.p.A. (Italy)
• Meridian Bioscience Inc. (U.S.)
• Quidel Corporation (U.S.)
• Siemens (Germany)
• Thermo Fisher Scientific Inc. (U.S.)
• Johnson and Johnson Private Limited (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Cepheid (U.S.)
• Qiagen (Germany)
• OraSure Technologies, Inc. (U.S.)

SKU-53759